[1] 朱剑萍，赵蕊 . 华法林药效的影响因素［J］．临床药物治疗杂志 ,2009, 7(3):55-58.[2] Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused updated incorporated into the ACC/AHA 2006guidelines for the management of patients with valvularheart diseases［J］．2008, 52(13): 141-2.[3] 王 斌 徐志云 叶小飞．华人心脏机械瓣膜置换术后华法林抗凝强度标准的系统评价［J］．国际心血管病杂志，2010,37(06):361-366.[4] 张瑜，游鹏程，郑秋山．115 例华法林临床应用调查分析［J］．中国药物警戒，2011，8 （9）: 524-527.[5] 孙云川 王 昕 秦明照 等．药物相互作用致心房颤动患者 INR 异常升高的病例分析及文献复习［J］．临床药物治疗杂志 2013,11(03):48-50.[6] Marusic S, Gojo-Tomic, Bacic-Vrca V, et al. Enhancedanticoagulant effect of warfarin in a patient treated withcloxacillin［J］．2012, 50(6): 431-3.[7] 中华医学会心血管病学分会 中国老年学学会心脑血管病专业委员会．华法林抗凝治疗的中国专家共识［J］．中华内科杂志 2013,11(03):48-50.[8] Teichert M, Van Noord C, Uitterlinden AG, et al.Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment［J］．Br J Haematol, 2011, 153(3): 379-85.[9] Li XQ, Andersson TB, Ahlstr 觟m M, et al. Comparisonof inhibitory effects of the proton pump -inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450activities［J］．Drug Metab Dispos, 2004, 32(8): 821-7.[10] McCarthy DM, McLaughlin T, Yazdani C, et al. Effects of co-therapy with early proton pump inhibitors(PPIs) on the occurrence of side effects of other drugswith potential for interaction with PPIs: a cohort study［C］．USA: WB SAUNDERS CO, 2002: A210-A210.